GET yields 4.26% · ABBV yields 3.12%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, GET + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GET + ABBV for your $10,000?
Getnet Adquirência e Serviços Para Meios de Pagamento S.A. operates in the acquiring and services market for means of payment regulated by the Council National Monetary Council and the Central Bank of Brazil. The company engages in the provision of accreditation services for retailer and service providers establishments to accept credit and debit cards; capturing, transmission, and processing of data and information; and installation, uninstallation, monitoring, supply, maintenance, and leasing of equipment used in transaction capture networks, such as point-of-sales devices, as well as acts as a distributor of telecommunication operators for the commercialization of telephony and data recharge digital credits. It is also involved in the management of payments and receipts made to establishments accredited to its network; development and selling or licensing of software; selling or distributing products and services from entities that provide registry information; provision of technical, commercial, and logistic infrastructure services for the business related to the receipt of bills from dealers, banks, and other collection documents; and issuing electronic currency. The company was formerly known as Farthi Empreendimentos e Participações S.A. and changed its name to Getnet Adquirência e Serviços para Meios de Pagamento S.A. in August 2014. The company was founded in 2003 and is headquartered in São Paulo, Brazil. Getnet Adquirência e Serviços para Meios de Pagamento S.A. is a subsidiary of PagoNxt Merchant Solutions, S.L.
Full GET Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.